VivoSim Labs, Inc.
VIVSHealthcare|Biotechnology|US
$0.14
+0.00 (+0.07%)
DCF Value
$1.67
Cash / Share
$0.32
Financials
Financial Snapshot
Market Cap
$2.3M
Enterprise Value
$994.6K
Revenue (TTM)
$112.0K
Net Income (TTM)
-$12.3M
Cash & Investments
$1.7M
Net Cash
$1.4M
Free Cash Flow (TTM)
-$10.1M
Operating CF (TTM)
-$10.1M
Debt/Equity
-0.13
Cash Runway & Burn Rate
Cash on Hand
$1.7M
Quarterly Burn
$2.5M
Monthly Burn
$841.7K
Est. Runway
~0.7 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $62.8M | $43.7M | $36.5M | $27.4M | $37.4M | $28.7M | $16.0M | $2.9M | $11.3M | $5.0M | $1.7M | |
| Operating Cash Flow | -$29.2M | -$28.9M | -$20.4M | -$14.9M | -$13.3M | -$8.5M | -$12.4M | -$14.7M | -$9.5M | -$10.8M | -$10.1M | |
| Free Cash Flow | -$30.5M | -$29.2M | -$20.5M | -$14.9M | -$13.7M | -$8.9M | -$12.8M | -$14.7M | -$9.5M | -$10.8M | -$10.1M | |
| Capital Expenditure | -$1.4M | -$296.0K | -$79.0K | $0.00 | -$405.0K | -$409.0K | -$396.0K | -$42.0K | -$13.0K | $0.00 | -$23.0K | |
| Financing Cash Flow | $31.2M | $10.1M | $13.2M | $4.9M | $23.8M | $205.0K | $0.00 | $1.4M | $8.8M | $4.4M | $2.6M |
R&D Spending
R&D (TTM)
$4.3M
R&D Intensity
3857.1%
R&D Growth vs Prior
+3.1%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.2M | $4.6M | $3.1M | $2.2M | $0.00 | $1.5M | $370.0K | $109.0K | $144.0K | $131.0K | $112.0K | |
| R&D Expense | $19.5M | $18.0M | $14.8M | $5.3M | $1.1M | $3.3M | $8.9M | $5.5M | $5.0M | $4.2M | $4.3M | |
| R&D % of Revenue | 462.1% | 390.1% | 477.3% | 240.6% | — | 221.3% | 2401.4% | 5044.0% | 3489.6% | 3197.7% | 3857.1% | |
| SG&A | $22.3M | $20.9M | $14.7M | $17.1M | $15.7M | $9.6M | $9.1M | $9.6M | $7.7M | $7.2M | $6.9M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.2M | $4.6M | $3.1M | $2.2M | $0.00 | $1.5M | $370.0K | $109.0K | $144.0K | $131.0K | $112.0K | |
| Cost of Revenue | $956.0K | $1.0M | $482.0K | $328.0K | $0.00 | $0.00 | $0.00 | $0.00 | $5.0K | $0.00 | $263.0K | |
| Gross Profit | $3.3M | $3.6M | $2.6M | $1.9M | $0.00 | $1.5M | $370.0K | $109.0K | $139.0K | $131.0K | -$151.0K | |
| R&D | $19.5M | $18.0M | $14.8M | $5.3M | $1.1M | $3.3M | $8.9M | $5.5M | $5.0M | $4.2M | $4.3M | |
| SG&A | $22.3M | $20.9M | $14.7M | $17.1M | $15.7M | $9.6M | $9.1M | $9.6M | $7.7M | $7.2M | $6.9M | |
| Operating Income | -$38.6M | -$35.3M | -$27.3M | -$21.5M | -$16.8M | -$11.5M | -$17.7M | -$15.1M | -$12.6M | -$11.2M | -$11.3M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $10.0K | $12.0K | $12.0K | |
| Pretax Income | -$38.4M | -$34.8M | -$26.6M | -$18.7M | -$16.8M | -$11.4M | -$17.3M | -$14.7M | -$2.5M | -$13.6M | -$12.3M | |
| Net Income | -$38.4M | -$34.8M | -$26.6M | -$18.7M | -$16.8M | -$11.4M | -$17.3M | -$14.7M | -$2.5M | -$13.8M | -$12.3M | |
| EPS (Diluted) | -94.38 | -77.89 | -55.40 | -34.66 | -29.25 | -15.78 | -23.77 | -19.25 | -1.70 | -5.35 | -6.04 | |
| EBITDA | -$37.4M | -$34.0M | -$26.3M | -$20.3M | -$14.0M | -$11.3M | -$17.0M | -$14.4M | -$2.2M | -$13.4M | -$12.1M | |
| Shares Out. (M) | 0.41 | 0.45 | 0.48 | 0.54 | 0.58 | 0.73 | 0.73 | 0.76 | 1.46 | 2.59 | 5.24 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $62.8M | $43.7M | $36.5M | $27.4M | $37.4M | $28.7M | $15.3M | $2.9M | $11.3M | $5.0M | $1.7M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $706.0K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $65.1M | $46.8M | $38.6M | $28.3M | $38.4M | $29.5M | $17.0M | $3.9M | $12.1M | $6.6M | $3.2M | |
| Total Assets | $69.2M | $49.8M | $40.6M | $28.4M | $39.9M | $33.3M | $20.3M | $6.3M | $14.7M | $7.4M | $3.8M | |
| Total Current Liabilities | $6.0M | $4.7M | $3.7M | $1.8M | $721.0K | $1.4M | $3.7M | $1.9M | $3.7M | $2.8M | $1.9M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $6.8M | $5.2M | $4.3M | $1.8M | $721.0K | $3.1M | $5.0M | $2.7M | $4.2M | $8.5M | $6.2M | |
| Stockholders' Equity | $62.4M | $44.6M | $36.3M | $26.6M | $39.2M | $30.2M | $15.3M | $3.6M | $10.5M | -$1.1M | -$2.3M | |
| Retained Earnings | -$199.3M | -$234.1M | -$260.8M | -$279.5M | -$296.3M | -$307.7M | -$325.0M | -$339.7M | -$342.2M | -$356.0M | -$357.3M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$29.2M | -$28.9M | -$20.4M | -$14.9M | -$13.3M | -$8.5M | -$12.4M | -$14.7M | -$9.5M | -$10.8M | -$10.1M | |
| Capital Expenditure | -$1.4M | -$296.0K | -$79.0K | $0.00 | -$405.0K | -$409.0K | -$396.0K | -$42.0K | -$13.0K | $0.00 | -$23.0K | |
| Free Cash Flow | -$30.5M | -$29.2M | -$20.5M | -$14.9M | -$13.7M | -$8.9M | -$12.8M | -$14.7M | -$9.5M | -$10.8M | -$10.1M | |
| Investing Cash Flow | -$1.4M | -$292.0K | -$76.0K | $747.0K | -$393.0K | -$409.0K | -$966.0K | $816.0K | $9.0M | $94.0K | $71.0K | |
| Financing Cash Flow | $31.2M | $10.1M | $13.2M | $4.9M | $23.8M | $205.0K | $0.00 | $1.4M | $8.8M | $4.4M | $2.6M | |
| Issuance of Stock | $30.7M | $9.4M | $13.3M | $5.0M | $23.8M | $251.0K | $0.00 | $1.4M | $8.8M | $4.8M | $3.0M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | -$1.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$363.0K | -$363.0K | |
| Stock Based Comp. | $7.4M | $6.9M | $5.2M | $4.1M | $5.6M | $2.3M | $2.4M | $1.5M | $532.0K | $303.0K | $316.0K | |
| Net Change in Cash | $660.0K | -$19.0M | -$7.3M | -$9.2M | $10.1M | -$8.7M | -$13.4M | -$12.4M | $8.4M | -$6.3M | -$7.4M |
Dilution Tracker
Shares outstanding grew 350.0% over 5 years — significant dilution
Shares Outstanding
17M
5-Year Share Growth
+350.0%
Stock Issuance (TTM)
$3.0M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.41 | 0.45 | 0.48 | 0.54 | 0.58 | 0.73 | 0.73 | 0.76 | 1.46 | 2.59 | 5.24 | |
| Change vs Prior % | — | 9.7% | 7.6% | 12.3% | 6.5% | 26.1% | 0.1% | 5.0% | 92.1% | 76.8% | 102.4% | |
| Stock Issuance | $30.7M | $9.4M | $13.3M | $5.0M | $23.8M | $251.0K | $0.00 | $1.4M | $8.8M | $4.8M | $3.0M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | -$1.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $7.4M | $6.9M | $5.2M | $4.1M | $5.6M | $2.3M | $2.4M | $1.5M | $532.0K | $303.0K | $316.0K |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 77.4% | 77.6% | 84.4% | 85.1% | — | 100.0% | 100.0% | 100.0% | 96.5% | 100.0% | -134.8% | |
| Operating Margin % | -911.9% | -766.3% | -882.4% | -977.9% | — | -765.3% | -4792.2% | -13840.4% | -8761.1% | -8567.9% | -10117.0% | |
| Net Margin % | -908.9% | -756.1% | -861.7% | -852.0% | — | -763.2% | -4664.6% | -13459.6% | -1727.8% | -10567.2% | -11016.1% | |
| EBITDA Margin % | -884.8% | -738.7% | -850.7% | -925.9% | — | -753.6% | -4584.9% | -13200.9% | -1534.7% | -10191.6% | -10827.7% | |
| FCF Margin % | -722.0% | -633.3% | -661.7% | -677.7% | — | -590.8% | -3460.5% | -13481.7% | -6579.2% | -8264.9% | -9038.4% | |
| ROE % | -61.7% | -78.1% | -73.4% | -70.3% | -42.9% | -37.9% | -112.6% | -407.4% | -23.7% | 1259.6% | -612.2% | |
| ROA % | -55.6% | -69.8% | -65.6% | -65.8% | -42.2% | -34.4% | -85.0% | -231.1% | -17.0% | -187.4% | -320.7% | |
| ROIC % | -61.1% | -78.1% | -73.9% | -80.6% | -42.9% | -35.4% | -103.5% | -302.0% | -110.3% | -222.3% | -499.2% | |
| R&D / Revenue % | 462.1% | 390.1% | 477.3% | 240.6% | — | 221.3% | 2401.4% | 5044.0% | 3489.6% | 3197.7% | 3857.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 185.2% | 8.8% | -32.8% | -29.0% | -100.0% | 0.0% | -75.3% | -70.5% | 32.1% | -9.0% | |
| Gross Profit | 120.8% | 9.1% | -27.0% | -28.4% | -100.0% | 0.0% | -75.3% | -70.5% | 27.5% | -5.8% | |
| Operating Income | 0.2% | 8.6% | 22.7% | 21.3% | 21.6% | 31.8% | -54.5% | 14.9% | 16.4% | 11.0% | |
| Net Income | 0.3% | 9.5% | 23.5% | 29.8% | 10.1% | 32.0% | -50.8% | 15.0% | 83.0% | -456.4% | |
| EPS (Diluted) | 8.2% | 17.5% | 28.9% | 37.4% | 15.6% | 46.1% | -50.6% | 19.0% | 91.2% | -214.7% | |
| Operating Cash Flow | 0.6% | 1.1% | 29.4% | 27.0% | 10.5% | 36.6% | -46.8% | -18.1% | 35.4% | -14.4% | |
| Free Cash Flow | 3.1% | 4.5% | 29.8% | 27.2% | 7.8% | 35.4% | -44.5% | -14.8% | 35.5% | -14.3% | |
| R&D Expense | 8.5% | -8.1% | -17.8% | -64.2% | -79.1% | 201.0% | 167.6% | -38.1% | -8.6% | -16.6% | |
| SG&A Expense | 0.8% | -6.3% | -29.6% | 16.7% | -8.4% | -38.7% | -5.6% | 6.1% | -20.3% | -6.8% | |
| Total Assets | 2.4% | -28.0% | -18.5% | -30.0% | 40.4% | -16.6% | -39.0% | -68.7% | 130.7% | -49.6% | |
| Book Value / Share | -7.6% | -34.8% | -24.3% | -34.7% | 38.1% | -38.9% | -49.3% | -77.6% | 51.7% | -105.9% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -17.3% | -22.8% | -32.4% | -52.5% | |
| Diluted Shares | 8.6% | 9.7% | 7.6% | 12.3% | 6.5% | 26.1% | 0.1% | 5.0% | 92.1% | 76.8% |
Valuation
P/E (TTM)At Loss
P/S20.97
10Y Low / Med / High0.17 / 0.83 / 28.25
P/B-0.32
10Y Low / Med / High0.01 / 0.03 / 0.36
EV/EBITDAAt Loss
10Y Low / Med / High0.01 / 1.36 / 3.55
EV/Revenue8.88
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.67
Cash / Share
$0.32
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.02 | -0.02 | -0.03 | -0.05 | -0.06 | -0.11 | -0.07 | -0.09 | -1.01 | -0.27 | -0.02 | |
| P/S Ratio | 0.17 | 0.17 | 0.27 | 0.42 | 0.00 | 0.83 | 3.38 | 12.03 | 17.48 | 28.25 | 20.97 | |
| P/B Ratio | 0.01 | 0.02 | 0.02 | 0.03 | 0.03 | 0.04 | 0.08 | 0.36 | 0.24 | -3.37 | -0.32 | |
| EV/EBITDA | 1.66 | 1.26 | 1.36 | 1.30 | 2.60 | 2.23 | 0.72 | 0.01 | 3.55 | 0.07 | -0.08 | |
| EV/Revenue | -14.67 | -9.33 | -11.53 | -12.03 | 0.00 | -16.83 | -33.10 | -1.80 | -54.53 | -6.68 | 8.88 |
Analyst Estimates & Quality
Altman Z-Score
-139.94
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2027 |
|---|---|
| Revenue | $232.0K |
| Net Income | -$23.3M |
| EPS | $-9.00 |
| # Analysts (EPS) | 1 |
Revenue Segments
By Product
| Segment | 2026 |
|---|---|
| Royalty | $131.0K |